<DOC>
	<DOC>NCT02945046</DOC>
	<brief_summary>This is a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to compare the efficacy and safety of 2 dose regimens of TEV-48125 versus placebo in adult patients for the prevention of ECH.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of TEV-48125 for the Prevention of Episodic Cluster Headache (ECH)</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<criteria>The patient has a history of ECH according to the International Classification of Headache Disorders 3rd edition (Beta version) (ICHD3 beta) criteria for ≥12 months prior to screening The patient has a total body weight of ≥45 kg (99 lbs.) The patient is in good health in the opinion of the investigator Women of childbearing potential (WOCBP) whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for the duration of the study Men must be sterile, or if they are potentially fertile/reproductively competent (not surgically [eg, vasectomy] or congenitally sterile) and their female partners are of childbearing potential, must use, together with their female partners, acceptable birth control Additional criteria apply, please contact the investigator for more information The patient has used short corticosteroid cycle to treat the current CH cycle. The patient has used an intervention/device (eg, scheduled nerve blocks) for headache during the 4 weeks prior to screening. The patient has clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, genitourinary, cardiac, neurologic, hepatic, or ocular disease at the discretion of the investigator. The patient has evidence or medical history of clinically significant psychiatric issues determined at the discretion of the investigator. The patient has known infection or history of human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection. The patient has a past or current history of cancer in the past 5 years, except for appropriately treated nonmelanoma skin carcinoma. The patient is pregnant or nursing. The patient has a history of hypersensitivity reactions to injected proteins, including monoclonal antibodies. The patient has participated in a clinical study of a monoclonal antibody, unless it is known that the patient received placebo during the study. The patient has a history of prior exposure to a monoclonal antibody targeting the calcitonin generelated peptide (CGRP) pathway (AMG 334, ALD304, LY2951742, or TEV48125). The patient is an employee of the sponsor/participating study center who is directly involved in the study or is the relative of such an employee. The patient has an implant for neurostimulation used in the treatment of CH. The patient is a member of a vulnerable population (eg, people kept in detention). The patient has a history of alcohol abuse prior to screening. Additional criteria apply, please contact the investigator for more information</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>